|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Hadassah Medical Organization |
|---|---|
| Information provided by: | Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT00159003 |
Purpose
There are naturally occuring variations in the genetic makeup of all of us. Some of these variations may contribute to a change in susceptibility toward different diseases or change the prognosis.
We are studying these genetic variations in patients with leukemia. The genes we are studying are those which influence detoxification of drugs and toxins.
| Condition |
|---|
|
Acute Myeloid Leukemia Chronic Lymphocytic Leukemia |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Molecular Analysis of Genetic Elements Which May Influence Predisposition and Prognosis of Hematological Malignancies in Different Ethnic Groups in Israel |
DNA only
| Estimated Enrollment: | 300 |
| Study Start Date: | January 1998 |
| Estimated Study Completion Date: | April 2011 |
We have prepared DNA on patients with leukemia (AML and CLL) and we are studying the influence of polymorphisms in drug metabolism and disposition genes on predisposition and prognosis of these types of leukemia. The genes we are studying include: MDR1, CYP3A4, NQO1, NAT1/2, GST. We plan to study other genes that may be contributory. Study includes comparing the frequency of polymorphisms in these genes with the frequency in the general population and the study of DNA biding proteins which bind at the sites of these polymorphisms.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients admitted to Hadassah Hospital with AML or CLL.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Deborah G Rund, MD | 972-2-6778712 | rund@cc.huji.ac.il |
| Israel | |
| Hadassah Medical Organization | Recruiting |
| Jerusalem, Israel, IL91120 | |
| Contact: Deborah G Rund, MD 972-2-6778712 rund@cc.huji.ac.il | |
| Principal Investigator: Deborah G Rund, MD | |
| Principal Investigator: | Deborah G Rund, MD | Hadassah Medical Organization |
More Information
| Responsible Party: | Hadassah Medical Organization ( Deborah Rund ) |
| Study ID Numbers: | 132910-HMO-CTIL |
| Study First Received: | September 8, 2005 |
| Last Updated: | February 12, 2009 |
| ClinicalTrials.gov Identifier: | NCT00159003 History of Changes |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
|
Leukemia, Lymphoid Immunoproliferative Disorders Disease Susceptibility Hematologic Neoplasms Hematologic Diseases Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia |
Lymphatic Diseases Chronic Lymphocytic Leukemia Acute Myelocytic Leukemia Leukemia, Lymphocytic, Chronic, B-Cell Genetic Predisposition to Disease Leukemia, B-cell, Chronic Leukemia, B-Cell Lymphoproliferative Disorders |
|
Leukemia, Lymphoid Disease Attributes Immunoproliferative Disorders Neoplasms by Histologic Type Immune System Diseases Disease Susceptibility Hematologic Neoplasms Hematologic Diseases Leukemia, Myeloid Leukemia, Myeloid, Acute |
Lymphatic Diseases Leukemia Neoplasms Neoplasms by Site Pathologic Processes Leukemia, Lymphocytic, Chronic, B-Cell Genetic Predisposition to Disease Lymphoproliferative Disorders Leukemia, B-Cell |
